NCT03767322

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 558 (estimated)
• Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

A randomized, placebo-controlled, double-blind clinical trial of effect of allopurinol or febuxostat to prevent contrast induced acute kidney injury (CI-AKI)

Detailed description

Eligible patients (patients with glomerular filtration rate \< 60 ml/min or high riks patients based on Mehran score) that will be undergoing cardiac catheterization/intervention randomly assigned to receive allopurinol 300 mg or febuxostat 80 mg 12 hours before and 12 after 1 exposure of radiocontrast and IV hydration (normal saline 1 ml/kg/hr 12 pre and post radiocontrast exposure) or placebo and hydration. Exclusion criteria: patients under treatment with allopurinol or febuxostat in the previous seven days, known allergy to allopurinol or febuxostat, patients on renal replacement therapy

Conditions

• Contrast-induced Nephropathy
• Contrast-induced Acute Kidney Injury

Interventions

Type	Name	Description
DRUG	Allopurinol	Eligible patients will receive allopurinol 300 mg before and after coronary intervention
DRUG	Febuxostat	Eligible patients will receive febuxostat 80 mg before and after coronary intervention
DRUG	Placebo	Eligible patients will receive before and after coronary intervention

Timeline

• Start date: 2018-12-05
• Primary completion: 2019-10-01
• Completion: 2019-12-01
• First posted: 2018-12-06
• Last updated: 2018-12-06

Locations

1 site across 1 country: Mexico